Explore this article's sources with AI
Follow PeptideMethods on Google
Dual and Triple Agonists for MASLD
A 2026 review maps dual and triple agonists for MASLD, but the underlying trials use different liver-fat, MASH and fibrosis endpoints.
Why we wrote this. A newly indexed review groups several agents together; this readout separates their liver-fat, MASH and fibrosis evidence.
In this article (6 sections)
A 2026 review argues that drugs acting at two or three metabolic hormone receptors could address several drivers of metabolic dysfunction-associated steatotic liver disease (MASLD). The most important caveat is that the review is not a new clinical trial. The underlying trials answer different questions: tirzepatide and survodutide have biopsy outcomes in MASH, while the retatrutide liver study measured liver fat by MRI in an obesity-trial substudy[1][2][3][4].
That distinction prevents an attractive receptor-count story from becoming a false ranking. Dual or triple agonism may affect appetite, glucose regulation, body weight and liver metabolism, but the trials do not establish that three receptor targets are better than two for treating MASH or fibrosis. Our separate retatrutide evidence page and tirzepatide evidence page cover each molecule outside this liver-specific comparison.
What the review actually adds
The Frontiers in Pharmacology paper is a narrative review of MASLD biology and a broad treatment pipeline. It discusses insulin resistance, excess lipid delivery to the liver and chronic inflammation, then groups therapies by the pathways they target. Its dual-agonist examples include tirzepatide, survodutide, cotadutide and pemvidutide. Retatrutide is the main triple GIP, GLP-1 and glucagon receptor agonist discussed[1].
The useful contribution is the map, not a pooled efficacy estimate. The review spans trials with different populations, durations and endpoints. Some enrolled people with biopsy-confirmed MASH and fibrosis. Another selected participants with at least 10% liver fat on MRI. These outcomes are related, but a fall in liver fat is not the same result as MASH resolution or fibrosis improvement on biopsy.
Tirzepatide and survodutide have biopsy readouts
The tirzepatide phase 2 study assigned 190 adults with biopsy-confirmed MASH and stage F2 or F3 fibrosis to tirzepatide or placebo for 52 weeks. MASH resolution without worsening fibrosis occurred in 44%, 56% and 62% of the 5 mg, 10 mg and 15 mg groups, compared with 10% on placebo. At least one-stage fibrosis improvement without worsening MASH occurred in 55%, 51% and 51%, compared with 30% on placebo[3]. These are dose-group results from a phase 2 trial, not personal treatment forecasts. PubMed also links the report to a 2026 correction notice[6].
The survodutide phase 2 trial enrolled 293 treated participants with biopsy-confirmed MASH and F1 through F3 fibrosis. Improvement in MASH without worsening fibrosis occurred in 47%, 62% and 43% across the three survodutide groups, versus 14% with placebo. At least one-stage fibrosis improvement occurred in 34%, 36% and 34%, versus 22% with placebo[4]. The non-monotonic response across dose groups is one reason not to turn the percentages into a simple more-drug-is-better claim.
Gastrointestinal events were prominent in both programs. The tirzepatide report describes the most common adverse events as gastrointestinal and mostly mild or moderate. In the survodutide trial, nausea affected 66% on active treatment and 23% on placebo, diarrhea 49% and 23%, and vomiting 41% and 4%, respectively[3][4]. Trial-level tolerability cannot determine whether a medicine is appropriate for an individual.
Retatrutide produced a large liver-fat signal
The retatrutide MASLD report was a 98-person substudy within a phase 2 obesity trial. Participants had at least 10% liver fat at baseline. At week 24, mean relative liver-fat changes were -42.9%, -57.0%, -81.4% and -82.4% across the 1 mg, 4 mg, 8 mg and 12 mg groups, compared with +0.3% on placebo[2].
Liver fat below 5% at week 24 occurred in 27%, 52%, 79% and 86% across those retatrutide groups, and in no placebo participants. Liver-fat reduction was associated with changes in weight, abdominal fat and metabolic measures[2]. This is a strong imaging signal, but the substudy did not provide biopsy evidence that retatrutide resolves MASH or reverses fibrosis. It also was not a head-to-head trial against tirzepatide or survodutide.
Pemvidutide shows why endpoints must stay separate
The newer IMPACT phase 2b readout studied 212 people with biopsy-confirmed MASH and F2 or F3 fibrosis. At week 24, MASH resolution without worsening fibrosis occurred in 58% with pemvidutide 1.2 mg and 52% with 1.8 mg, versus 20% with placebo. However, fibrosis improvement without worsening MASH was 33% and 36%, versus 28% with placebo, and those differences did not meet the trial's statistical threshold[5].
A positive MASH-resolution endpoint does not automatically establish a fibrosis benefit. Fibrosis may require longer observation, but that is a hypothesis for longer trials rather than a result from this 24-week analysis. The same discipline applies across the field: imaging, inflammation and fibrosis findings should be reported separately.
What we do not yet know
No trial reviewed here directly compared a dual agonist with a triple agonist for liver outcomes. Cross-trial comparisons are especially unreliable because entry criteria, fibrosis stages, dose schedules, treatment durations, missing-data methods and endpoint definitions differ. The studies were also phase 2 programs, so larger and longer trials are needed to assess durability, uncommon harms and clinical outcomes such as cirrhosis complications.
Mechanistic plausibility is not a regulatory indication. Tirzepatide has clinical uses outside this article's liver question, while retatrutide, survodutide and pemvidutide remain development programs rather than interchangeable MASLD treatments. Approval status, product labeling and evidence for a specific liver population must be checked separately from receptor pharmacology.
Bottom line
The review captures a genuine shift toward multi-receptor metabolic drugs in MASLD research. Tirzepatide and survodutide produced encouraging biopsy-based MASH results, pemvidutide met its MASH-resolution endpoint but not its fibrosis endpoint at 24 weeks, and retatrutide produced a large MRI liver-fat reduction in a small substudy. Those findings support further trials. They do not prove that triple agonism is superior to dual agonism, or that liver-fat reduction guarantees fibrosis reversal.
Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.
Frequently asked
Is the 2026 dual and triple agonist paper a clinical trial?
No. It is a narrative review. Its treatment claims must be checked against the underlying randomized trials, which studied different populations and liver endpoints.
What did the retatrutide MASLD substudy measure?
It primarily measured relative change in liver fat by MRI at 24 weeks in 98 participants with at least 10% liver fat. It did not provide biopsy proof of MASH resolution or fibrosis improvement.
Did tirzepatide and survodutide improve MASH?
In separate placebo-controlled phase 2 trials, both produced higher rates of biopsy-based MASH improvement or resolution without worsening fibrosis. They were not compared head to head.
Are triple agonists proven better than dual agonists for MASLD?
No. Receptor count cannot be used as a clinical ranking. No trial reviewed here directly compared dual and triple agonists using the same liver population and endpoint.
Sources
- [1]Alsharif et al. From pathophysiology to therapy: dual and triple agonists as a new frontier in MASLD. Frontiers in Pharmacology. 2026. PMID 42947668.Tier 2 · expert↩
- [2]Sanyal et al. Triple hormone receptor agonist retatrutide for MASLD: randomized phase 2a trial. Nature Medicine. 2024. PMID 38858523.Tier 1 · primary↩
- [3]Loomba et al. Tirzepatide for MASH with liver fibrosis, phase 2 trial. New England Journal of Medicine. 2024. PMID 38856224.Tier 1 · primary↩
- [4]Sanyal et al. Phase 2 randomized trial of survodutide in MASH and fibrosis. New England Journal of Medicine. 2024. PMID 38847460.Tier 1 · primary↩
- [5]Noureddin et al. Pemvidutide versus placebo for MASH, IMPACT phase 2b 24-week results. Lancet. 2025. PMID 41237796.Tier 1 · primary↩
- [6]Correction notice for Tirzepatide for MASH with Liver Fibrosis. New England Journal of Medicine. 2026. PMID 41880634.Tier 1 · primary↩
No revisions yet. First published .